Global News reported that, according to Felix, a Canadian integrated health-care platform, the average cost of Ozempic injections can be between $200 and $450 per month depending on the province
Lilly is expecting another revenue rise of around 32% in 2025, and analysts are expecting it to grow its share of the GLP-1 market across diabetes and obesity (it ended 2024 with 34% compared with Novo Nordisks 63%)
For instance, the OASIS 1 trial found a mean weight loss of 14.9% for those on semaglutide tablets, compared to just 2.4% in the placebo group
These compounded GLP-1 drugs may include custom microdose formulations, and some are marketed for off-label uses like longevity or cognitive support, though experts warn that their safety and effectiveness remain unproven
Tirzepatide tends to produce more weight loss than semaglutide, often by a meaningful margin in head-to-head data